Long-Term Cardiovascular Outcomes in Systemic Lupus Erythematosus

Yafasova, Adelina; Fosbøl, Emil Loldrup; Schou, Morten; Baslund, Bo; Faurschou, Mikkel; Docherty, Kieran F.; Jhund, Pardeep S.; McMurray, John J.V.; Sun, Guoli; Kristensen, S L; Torp‐Pedersen, Christian; Køber, Lars; Butt, Jawad H

doi:10.1016/j.jacc.2021.02.029

Cited by 53 publications

(50 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…See Figure 1 for the experimental flow chart. (4) patients with other malignant tumors, neurodegenerative diseases, and mental diseases; and (5) unwilling to participate in the investigation. Patients diagnosed with SLE and not having any feature of the exclusion criteria could be included in this study.…”

Section: Methodsmentioning

confidence: 99%

“…Because clinical heterogeneity leads to different clinical manifestations and outcomes in SLE patients, clinical heterogeneity makes no certain single detection method available to confirm SLE [3]. Studies have shown that the etiology of SLE may be environmental factors, genetic factors, and hormones and interactions and that genetic factors may play a key role in the pathogenesis of SLE [4,5].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Study on the Relationship between lncRNA Gene Polymorphism and Systemic Lupus Erythematosus

Guan

Liú

Xing

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Background. Systemic lupus erythematosus (SLE) is an autoimmune disease that can cause damage to multiple systems of the body. A number of studies have shown that long-chain noncoding RNA (lncRNA) can participate in the occurrence and development of a variety of autoimmune diseases. This study is aimed at detecting the expression levels of 5 lncRNAs in SLE patients and healthy controls and at exploring the relationship between expression levels and clinical symptoms and laboratory indicators. Methods. The design type of this study is a case-control study. A total of 76 SLE patients and 71 healthy controls were included in the first phase of the study. Real-time fluorescence quantitative polymerase chain reaction was used to detect the expression level of 5 kinds of lncRNAs including lnc7514, lnc0640, lncagf, nc3643, and lnc5150 in PBMCs of two groups of patients; the expression of lncRNAs in the case group and the control group was analyzed. We analyzed the differences in the expression levels of lncRNAs between case and control groups, and explored the association of expression levels with clinical manifestations and laboratory characteristics. SPSS23.0 was used to analyze the expression level and gene polymorphism results; the statistical analysis test level α = 0.05 . Results. The expression level of lnc0640 in PBMCs of SLE patient group was higher than that of healthy control group ( Z = − 3.56 , P = 0.03 ). However, lnc5150 was lower than in healthy controls ( Z = − 7.16 , P < 0.001 ). lnc3643 expression levels were lower in SLE patients of SLE patients with pleurisy was lower than that of patients without pleurisy ( Z = − 2.44 , P = 0.02 ). Low lnc3643 expression levels were observed in PBMCs with SLE patients with rash symptoms ( Z = − 2.75 , P = 0.013 ). SLE expressed lower lnc3643 levels in PBMCs with SLE compared with those without pleurisy ( Z = − 2.42 , P = 0.02 ). The above differences were statistically significant. Association analysis of lncRNA expression levels and clinical manifestations in SLE patients found that SLE was lower than those without rash or pleurisy (both P < 0.05 ); association analysis of lncRNA expression level and laboratory results found a negative correlation between lnc3643, lnc7514, and SLE disease activity score (SLEDAI-2K), blood sink (ESR), and C-reactive protein (CRP) (all P < 0.05 ). Conclusions. lnc0640 was overexpressed in PBMCs in SLE patients compared with healthy controls. lnc3643 was negatively correlated with SLEDAI, and expression levels were associated with SLE patients with arthritis, rash, and pleuritis.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Study on the Relationship between lncRNA Gene Polymorphism and Systemic Lupus Erythematosus

Guan

Liú

Xing

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

show abstract

“…This could partly explain the well-known long-term CV outcomes of SLE patients, characterized by high rate of heart failure and major heart ischemic events. 9 Limitation of our data are the lack of invasive validation for the index cfPWV/ GLS as a surrogate of VAC and, more importantly, the acknowledgment that both its components are not elastances and so theoretically the index cannot represent VAC itself. 4 To conclude, we strongly suggest referring SLE patients early to a global CV assessment with tools able to assess preclinical heart and vascular alterations, in order to set up an adequate follow-up and improve their survival.…”

mentioning

confidence: 93%

Ventricular-arterial coupling in systemic lupus erythematosus women without cardiovascular risk factors

Sciatti

Cavazzana

Franceschini

et al. 2022

Lupus

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is characterized by endothelial dysfunction, arterial stiffness, and myocardial impairment. We aimed at analyzing the ratio between carotid-femoral pulse wave velocity (cfPWV) and left ventricular global longitudinal strain (GLS) as a new index to approximate ventricular-arterial coupling (VAC) in women with SLE and without cardiovascular risk factors. Half cases had impaired GLS and consequently a hampered ratio. We thus suggest referring SLE patients early to a CV prevention program.

show abstract

“…Lipids participate in many biological processes and take part in a complex network of bioactive compounds and biochemical reactions. They act as inducers, suppressors, modulators, cellular structuring and signaling compounds, and mediators in many pathways, including inflammatory pathways [ 1 , 2 ]. Profiling lipids in human samples might advance the discovery of diagnostic, prognostic, and monitoring disease biomarkers, in addition to allowing the exploration of biological mechanisms [3] .…”

mentioning

confidence: 99%

“…Lipidomics can be used to develop new clinical tools and advance the understanding of homeostatic and inflammatory processes related to chronic inflammatory systemic diseases such as atherosclerosis-related vascular diseases, including cardiovascular diseases (CVD), stable and unstable angina pectoris, myocardial infarction, and ischemic stroke (IS), as well as diseases with a high incidence of atherosclerotic and cardiovascular events such as systemic lupus erythematosus (SLE) [ 5 , 2 ]. The etiological mechanisms of inflammation for these chronic inflammatory diseases involve a complex and dynamic network that has not been fully elucidated.…”

mentioning

confidence: 99%